抗ウイルス薬の世界市場レポート 2025年

抗ウイルス薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は7.6%で、1,536億7,000万米ドルに成長します。予測期間の成長は、新たなウイルスの脅威、世界の健康イニシアチブに起因しています。予測期間の主な動向には、技術の進歩、遠隔医療とデジタルヘルス、個別化医療などがあります。

インフルエンザ罹患率の上昇が抗ウイルス薬市場の成長を促進すると予想されます。一般にインフルエンザとして知られるインフルエンザは、インフルエンザウイルスによって引き起こされる感染力の強いウイルス性呼吸器感染症です。抗ウイルス薬は、これらのウイルスの体内での複製と拡散を阻害することにより、インフルエンザの治療に使用されます。例えば、2022年10月、米国の保健機関である疾病対策予防センター（CDC）は、2021～2022年のインフルエンザシーズン中に、900万人のインフルエンザ罹患者、400万人のインフルエンザ関連受診者、10万人のインフルエンザ関連入院者、5,000人のインフルエンザ死亡者が出たと報告しました。このようなインフルエンザ罹患率の増加は、抗ウイルス薬市場の成長に寄与する重要な要因です。

ライフサイエンス研究に対する官民の資金援助が世界的に拡大していることは、抗ウイルス薬治療市場の成長を加速させると予想されます。現在、COVID-19の治療薬として承認されている薬剤やワクチンはありませんが、承認や発売を待っているワクチンや治療薬がいくつかパイプラインにあります。世界各国の政府は、ワクチン、治療、診断の研究を支援する新しい助成基金を導入しています。例えば、2023年3月、英国の政府機関であるGov.UKは、英国のライフサイエンス企業4社とともに、ライフサイエンス革新的製造基金から2億7,700万英ポンド（3億578万米ドル）の最初の資金を受けました。このイニシアティブにより、民間投資がさらに2億6,000万ポンド（2億8,701万米ドル）促進され、320の新規雇用が創出され、199の既存雇用が保護される見込みです。これは、この分野で224の新規雇用を確保し、345の雇用を保護した、7,500万英ポンド（8,279万米ドル）の前回の試験的基金に続くものです。このように、ライフサイエンス研究に対する官民出資の増加は、研究開発努力を後押しし、それによって抗ウイルス薬治療市場の成長を促進すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の抗ウイルス薬市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の抗ウイルス薬市場：成長率分析
• 世界の抗ウイルス薬市場の実績：規模と成長、2019～2024年
• 世界の抗ウイルス薬市場の予測：規模と成長、2024～2029年、2034年
• 世界の抗ウイルス薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗ウイルス薬市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 先発
• ジェネリック
• 世界の抗ウイルス薬市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• DNAポリメラーゼ阻害剤
• 逆転写酵素阻害剤
• プロテアーゼ阻害剤
• ノイラミニダーゼ阻害剤
• その他
• 世界の抗ウイルス薬市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• HIV
• 肝炎
• ヘルペス
• インフルエンザ
• その他
• 世界の抗ウイルス薬市場：先発のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• HIVまたはAIDS抗ウイルス薬
• 肝炎抗ウイルス薬
• インフルエンザ抗ウイルス薬
• 単純ヘルペスウイルス（HSV）抗ウイルス薬
• 世界の抗ウイルス薬市場：ジェネリックのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ジェネリックHIVまたはAIDS抗ウイルス薬
• ジェネリック肝炎抗ウイルス薬
• ジェネリックインフルエンザ抗ウイルス薬
• ジェネリック単純ヘルペスウイルス（HSV）抗ウイルス薬

第7章 地域別・国別分析

• 世界の抗ウイルス薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の抗ウイルス薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗ウイルス薬市場：競合情勢
• 抗ウイルス薬市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers-Squibb Co. Overview, Products and Services, Strategy and Financial Analysis
  • Chemical Industrial & Pharmaceutical Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline Plc
• Johnson & Johnson Services Ltd.
• Merck & Co. Inc.
• Dr. Reddy's Laboratories Ltd.
• AstraZeneca plc
• Aurobindo Pharma Ltd.
• Abbott Laboratories
• Schering-Plough Corporation
• Pfizer Inc.
• Sanofi-Synthelabo Ltd.
• Regeneron Pharmaceuticals Inc.
• Inovio Pharmaceuticals Inc.
• Novavax Inc.
• BioCryst Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 抗ウイルス薬市場2029：新たな機会を提供する国
• 抗ウイルス薬市場2029：新たな機会を提供するセグメント
• 抗ウイルス薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Anti-viral drug therapy encompasses the use of medications to combat viral infections, including diseases like human immunodeficiency virus (HIV), hepatitis, influenza, and emerging viruses like the novel COVID-19. These drugs work by inhibiting the replication and spread of viruses rather than directly killing them. The anti-viral drug sector primarily comprises establishments engaged in the production of various classes of antiviral drugs, including DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others.

The primary categories of anti-viral drug therapy include branded and generic medications. These drugs belong to different classes tailored for specific viral infections, including HIV, hepatitis, herpes, influenza, and more. Among these, reverse-transcriptase inhibitors (RTIs) are a noteworthy class used for treating HIV and, in some cases, hepatitis B infections.

The anti-viral drug therapy market research report is one of a series of new reports from The Business Research Company that provides anti-viral drug therapy market statistics, including anti-viral drug therapy industry global market size, regional shares, competitors with an anti-viral drug therapy market share, detailed anti-viral drug therapy market segments, market trends and opportunities, and any further data you may need to thrive in the anti-viral drug therapy industry. This anti-viral drug therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antivirals market size has grown strongly in recent years. It will grow from $106.13 billion in 2024 to $114.7 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to viral disease prevalence, public health concerns, patent expirations, government initiatives.

The antivirals market size is expected to see strong growth in the next few years. It will grow to $153.67 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to emerging viral threats, global health initiatives. Major trends in the forecast period include technological advances, telemedicine and digital health, personalized medicine.

The rising incidence of influenza is expected to drive the growth of the antiviral market. Influenza, commonly known as the flu, is a highly contagious viral respiratory infection caused by influenza viruses. Antiviral medications are used to treat influenza by inhibiting the replication and spread of these viruses within the body. For instance, in October 2022, the Centers for Disease Control and Prevention (CDC), a US-based health agency, reported that during the 2021-2022 flu season, there were 9 million flu illnesses, 4 million flu-related medical visits, 100,000 flu-related hospitalizations, and 5,000 flu deaths. This increasing incidence of influenza is a key factor contributing to the growth of the antiviral market.

The growing public-private funding for life science research globally is expected to accelerate the growth of the antiviral drug therapy market. While no drugs or vaccines are currently approved for the treatment of COVID-19, several vaccines and therapies are in the pipeline awaiting approval or launch. Governments worldwide have introduced new grant funds to support research in vaccines, treatments, and diagnostics. For example, in March 2023, Gov.UK, a UK-based government agency, alongside four UK life sciences companies, received the first tranche of £277 million ($305.78 million) from the Life Sciences Innovative Manufacturing Fund. This initiative is expected to facilitate an additional £260 million ($287.01 million) in private investment, create 320 new jobs, and safeguard 199 existing ones. This follows a previous pilot fund of £75 million ($82.79 million), which secured 224 new jobs and protected 345 positions in the sector. As such, the increase in public-private funding for life science research is anticipated to boost research and development efforts, thereby driving the growth of the COVID-19 antiviral drug therapy market.

Major companies operating in the antiviral market are focusing on developing innovative treatments, such as oral antiviral medications, to improve patient compliance, enhance accessibility, reduce healthcare costs, and provide more convenient and effective options for managing viral infections. Oral antiviral treatments are taken by mouth and work by inhibiting the replication or spread of viruses in the body, helping to reduce the severity and duration of infections. For example, in May 2023, Pfizer, a US-based pharmaceutical company, announced the approval of Paxlovid by the Food and Drug Administration (FDA). This marked the first oral antiviral treatment for COVID-19 in adults. The approval is significant as it provides a new therapeutic option for managing COVID-19, especially as the pandemic transitions to an endemic phase. Paxlovid is indicated for adults with mild-to-moderate COVID-19 who are at high risk of progression to severe disease, including hospitalization or death. This treatment is expected to improve patient outcomes while offering a more convenient, oral option compared to intravenous treatments.

Major companies in the antiviral market are increasingly focused on developing advanced therapeutic solutions, such as antiviral treatments, to improve patient outcomes and reduce viral transmission. These treatments are crucial for managing viral infections and preventing complications in affected patients. For example, in August 2024, Red Queen's Technology, a US-based pharmaceutical company, launched a new line of versatile antivirals. Apple Tree Partners invested $55 million in Red Queen Therapeutics, a biotech firm working on broad-spectrum antiviral treatments. The company targets infectious pathogens such as COVID-19 and influenza, having already advanced a COVID antiviral through Phase 1 testing and secured U.S. government funding for a pan-influenza drug. Co-founded by Harvard professor Loren Walensky, Red Queen uses stapled lipopeptides to inhibit viral fusion and block viral entry into cells.

In June 2022, Pfizer Inc., a leading US-based pharmaceutical company, completed its acquisition of ReViral Ltd. for $525 million. This strategic acquisition is part of Pfizer's effort to expand its anti-infective pipeline and strengthen its dedication to developing medications and vaccines for combating respiratory syncytial virus (RSV). ReViral Ltd., a UK-based company, specializes in the development of antiviral drugs. This acquisition enhances Pfizer's position in the fight against viral infections, particularly RSV, and represents a significant investment in the development of antiviral treatments.

Major companies operating in the antivirals market include AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy's Laboratories Ltd., AstraZeneca plc, Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthelabo Ltd., Regeneron Pharmaceuticals Inc., Inovio Pharmaceuticals Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Argos Distributors Limited, AVI Biopharma International Ltd., Moderna Inc., BioNTech SE, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.

North America was the largest region in the anti-viral drug therapy market in 2024. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antivirals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-viral drug therapy market consists of sales of amantadine and rimantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antivirals Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antivirals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antivirals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antivirals market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Branded; Generic
• 2) By Drug Class: DNA Polymerase Inhibitors; Reverse Transcriptase Inhibitors; Protease Inhibitors; Neuraminidase Inhibitors; Other Drug classes
• 3) By Application: HIV; Hepatitis; Herpes; Influenza; Other Applications
• Subsegments:
• 1) By Branded: Antivirals For HIV Or AIDS; Antivirals For Hepatitis; Antivirals For Influenza; Antivirals For Herpes Simplex Virus (HSV)
• 2) By Generic: Generic HIV Or AIDS Antivirals; Generic Hepatitis Antivirals; Generic Influenza Antivirals; Generic Herpes Simplex Virus (HSV) Antivirals
• Companies Mentioned: AbbVie Inc.; Bristol-Myers-Squibb Co.; Chemical Industrial & Pharmaceutical Laboratories Ltd.; F. Hoffmann-La Roche Ltd.; Gilead Sciences Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antivirals Market Characteristics

3. Antivirals Market Trends And Strategies

4. Antivirals Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Antivirals Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antivirals PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antivirals Market Growth Rate Analysis
• 5.4. Global Antivirals Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antivirals Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antivirals Total Addressable Market (TAM)

6. Antivirals Market Segmentation

• 6.1. Global Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branded
• Generic
• 6.2. Global Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• DNA Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Neuraminidase Inhibitors
• Other Drug Classes
• 6.3. Global Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HIV
• Hepatitis
• Herpes
• Influenza
• Other Applications
• 6.4. Global Antivirals Market, Sub-Segmentation Of Branded, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antivirals For HIV Or AIDS
• Antivirals For Hepatitis
• Antivirals For Influenza
• Antivirals For Herpes Simplex Virus (HSV)
• 6.5. Global Antivirals Market, Sub-Segmentation Of Generic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic HIV Or AIDS Antivirals
• Generic Hepatitis Antivirals
• Generic Influenza Antivirals
• Generic Herpes Simplex Virus (HSV) Antivirals

7. Antivirals Market Regional And Country Analysis

• 7.1. Global Antivirals Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antivirals Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antivirals Market

• 8.1. Asia-Pacific Antivirals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antivirals Market

• 9.1. China Antivirals Market Overview
• 9.2. China Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antivirals Market

• 10.1. India Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antivirals Market

• 11.1. Japan Antivirals Market Overview
• 11.2. Japan Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antivirals Market

• 12.1. Australia Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antivirals Market

• 13.1. Indonesia Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antivirals Market

• 14.1. South Korea Antivirals Market Overview
• 14.2. South Korea Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antivirals Market

• 15.1. Western Europe Antivirals Market Overview
• 15.2. Western Europe Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antivirals Market

• 16.1. UK Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antivirals Market

• 17.1. Germany Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antivirals Market

• 18.1. France Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antivirals Market

• 19.1. Italy Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antivirals Market

• 20.1. Spain Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antivirals Market

• 21.1. Eastern Europe Antivirals Market Overview
• 21.2. Eastern Europe Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antivirals Market

• 22.1. Russia Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antivirals Market

• 23.1. North America Antivirals Market Overview
• 23.2. North America Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antivirals Market

• 24.1. USA Antivirals Market Overview
• 24.2. USA Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antivirals Market

• 25.1. Canada Antivirals Market Overview
• 25.2. Canada Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antivirals Market

• 26.1. South America Antivirals Market Overview
• 26.2. South America Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antivirals Market

• 27.1. Brazil Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antivirals Market

• 28.1. Middle East Antivirals Market Overview
• 28.2. Middle East Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antivirals Market

• 29.1. Africa Antivirals Market Overview
• 29.2. Africa Antivirals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antivirals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antivirals Market Competitive Landscape And Company Profiles

• 30.1. Antivirals Market Competitive Landscape
• 30.2. Antivirals Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol-Myers-Squibb Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Chemical Industrial & Pharmaceutical Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Antivirals Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline Plc
• 31.2. Johnson & Johnson Services Ltd.
• 31.3. Merck & Co. Inc.
• 31.4. Dr. Reddy's Laboratories Ltd.
• 31.5. AstraZeneca plc
• 31.6. Aurobindo Pharma Ltd.
• 31.7. Abbott Laboratories
• 31.8. Schering-Plough Corporation
• 31.9. Pfizer Inc.
• 31.10. Sanofi-Synthelabo Ltd.
• 31.11. Regeneron Pharmaceuticals Inc.
• 31.12. Inovio Pharmaceuticals Inc.
• 31.13. Novavax Inc.
• 31.14. BioCryst Pharmaceuticals Inc.
• 31.15. Alnylam Pharmaceuticals Inc.

32. Global Antivirals Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antivirals Market

34. Recent Developments In The Antivirals Market

35. Antivirals Market High Potential Countries, Segments and Strategies

• 35.1 Antivirals Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antivirals Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antivirals Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer